Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Camco Financial Corporation Buyout
NEW YORK, Oct. 10, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Camco Financial Corporation ("Camco" or the "Company") (NasdaqGM:CAFI) related to the proposed acquisition of the Company by Huntington Bancshares Inc. (NasdaqGS:HBAN). The transaction is valued at around $97 million.
This investigation concerns whether the Board of Directors of Camco breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. Under the terms of the agreement, Camco shareholders will receive either $6.00 in cash or 0.7264 shares of Huntington common stock for each share of Camco common stock owned.
If you are aware of any facts relating to this investigation, or purchased shares of Camco Financial Corporation, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE Bronstein, Gewirtz & Grossman, LLC
More by this Source
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INTL FCStone, Inc.
Dec 19, 2013, 08:45 ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INSYS Therapeutics, Inc.
Dec 13, 2013, 10:26 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.